Minireview: RET: Normal and abnormal functions

Endocrinology

Volumn 145, Issue 12, 2004, Pages 5448-5451

  Santoro, Massimo ^a   Melillo, Rosa Marina ^a   Carlomagno, Francesca ^a   Vecchio, Giancarlo ^a   Fusco, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; TYROSINE KINASE RECEPTOR;

CARCINOGENESIS; GENE MUTATION; HERITABILITY; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 9444272942     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0922     Document Type: Short Survey

References (43)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S 2002 The protein kinase complement of the human genome. Science 298:1912-1934
2. Gschwind A, Fischer OM, Ullrich A 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-370
3. Schlessinger J, Lemmon MA 2003 SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003:RE12
4. Airaksinen MS, Saarma M 2002 The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394
5. Manie S, Santoro M, Fusco A, Billaud M 2001 The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17: 580-589
6. de Graaff E, Srinivas S, Kilkenny C, D'Agati V, Mankoo BS, Costantini F, Pachnis V 2001 Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15:2433-2444
7. Pachnis V, Mankoo B, Costantini F 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119:1005-1017
8. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V 1994 Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383
9. Ibanez C 2001 Response: GDNF recruits the signaling crew into lipid rafts. Trends Neurosci 24:429
10. Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE 1996 Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 271:5309-5312
11. Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R, Kato M, Suzuki H, Takahashi M, Nakashima I 2004 Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279:14213-14224
12. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A, Santoro M 2000 Tyrosines 1015 and 1062 are in vivo autophosphorylarion sites in ret and ret-derived oncoproteins. J Clin Endocrinol Metab 85:3898-3907
13. Coulpier M, Anders J, Ibanez CF 2002 Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277:1991-1999
14. Ichihara M, Murakumo Y, Takahashi M 2004 RET and neuroendocrine rumors. Cancer Lett 204:197-211
15. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR 2004 A census of human cancer genes. Nat Rev Cancer 4:177-183
16. Blume-Jensen P, Hunter T 2001 Oncogenic kinase signalling. Nature 411: 355-365
17. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
18. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
19. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H; European Multiple Endocrine Neoplasia (EUROMEN) Study Group 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525
20. Bugalho MJ, Domingues R, Sobrinho L 2003 Molecular diagnosis of multiple endocrine neoplasia type 2. Expert Rev Mol Diagn 3:769-777
21. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, Neumann HP 2000 Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85:4568-4574
22. Santoto M, Carlomagno F, Romano A, Bottato DP, Dathan NA, Grieco M, Vecchio G, Fusco A, Kraus M, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383
23. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M 1999 Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 13:331-336
24. Jain S, Watson MA, DeBenedetti MK, Hiraki Y, Moley JF, Milbrandt J 2004 Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 64:3907-3913
25. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer UD, Mannan P, Lubensky IA, Chrousos GP, Gagel RF, Pacak K, Zhuang Z 2000 Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res 60: 6223-6226
26. Huang SC, Torres-Cruz J, Pack SD, Koch CA, Vortmeyer AO, Mannan P, Lubensky IA, Gagel RF, Zhuang Z 2003 Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab 88:459-463
27. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511
28. Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 19: 5590-5597
29. Williams D 2002 Cancer after nuclear fallout: lessons from the Chemobyl accident. Nat Rev Cancer 2:543-549
30. Mizuno T, Iwamoto KS, Kyoizumi S, Nagamura H, Shinohara T, Koyama K, Seyama T, Hamatani K 2000 Preferential induction of RET/PTC1 rearrangement by x-ray irradiation. Oncogene 19:438-443
31. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE 2000 Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290:138-141
32. Cote GJ, Gagel RF 2003 Lessons learned from the management of a rare genetic cancer. N Engl J Med 349:1566-1568
33. Yano L, Shimura M, Taniguchi M, Hayashi Y, Suzuki T, Hatake K, Takaku F, Ishizaka Y 2000 Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 11:995-1004
34. Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I 2002 Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. Biochem Biophys Res Commun 294:813-817
35. Minna JD, Gazdar AF, Sprang SR, Herz J 2004 Cancer. A bull's eye for targeted lung cancer therapy. Science 304:1458-1461
36. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62:1077-1082
37. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP2). J Clin Endocrinol Metab 88:1897-1902
38. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I 2003 PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 63:2234-2243
39. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F 2004 Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96:1006-1014
40. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD 2003 CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63:5559-5563
41. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
42. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056-6063
43. Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM, Santoto M 2004 Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 64:3823-3829